» Articles » PMID: 30258051

Structural Basis for Broad Neutralization of Ebolaviruses by an Antibody Targeting the Glycoprotein Fusion Loop

Overview
Journal Nat Commun
Specialty Biology
Date 2018 Sep 28
PMID 30258051
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The severity of the 2014-2016 ebolavirus outbreak in West Africa expedited clinical development of therapeutics and vaccines though the countermeasures on hand were largely monospecific and lacked efficacy against other ebolavirus species that previously emerged. Recent studies indicate that ebolavirus glycoprotein (GP) fusion loops are targets for cross-protective antibodies. Here we report the 3.72 Å resolution crystal structure of one such cross-protective antibody, CA45, bound to the ectodomain of Ebola virus (EBOV) GP. The CA45 epitope spans multiple faces of the fusion loop stem, across both GP1 and GP2 subunits, with ~68% of residues identical across > 99.5% of known ebolavirus isolates. Extensive antibody interactions within a pan-ebolavirus small-molecule inhibitor binding cavity on GP define this cavity as a novel site of immune vulnerability. The structure elucidates broad ebolavirus neutralization through a highly conserved epitope on GP and further enables rational design and development of broadly protective vaccines and therapeutics.

Citing Articles

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.

Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S bioRxiv. 2025; .

PMID: 40060701 PMC: 11888476. DOI: 10.1101/2025.03.02.641072.


Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.

Bu F, Ye G, Morsheimer K, Mendoza A, Turner-Hubbard H, Herbst M PLoS Pathog. 2024; 20(12):e1012817.

PMID: 39715280 PMC: 11723632. DOI: 10.1371/journal.ppat.1012817.


Delayed treatment of cynomolgus macaques with a FVM04/CA45 monoclonal antibody cocktail provides complete protection against lethal Sudan virus infection.

Chan M, Warner B, Audet J, Barker D, Tailor N, Vendramelli R J Virol. 2024; 98(8):e0124223.

PMID: 39012096 PMC: 11334508. DOI: 10.1128/jvi.01242-23.


Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization.

Janus B, Wang R, Cleveland 4th T, Metcalf M, Lemmer A, van Dyk N J Virol. 2024; 98(7):e0015524.

PMID: 38832790 PMC: 11329191. DOI: 10.1128/jvi.00155-24.


The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus.

Yu X, Hastie K, Davis C, Avalos R, Williams D, Parekh D Cell Rep. 2023; 42(11):113366.

PMID: 37938974 PMC: 11045044. DOI: 10.1016/j.celrep.2023.113366.


References
1.
Weissenhorn W, Carfi A, Lee K, Skehel J, Wiley D . Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell. 1998; 2(5):605-16. DOI: 10.1016/s1097-2765(00)80159-8. View

2.
Harrison S . Viral membrane fusion. Virology. 2015; 479-480:498-507. PMC: 4424100. DOI: 10.1016/j.virol.2015.03.043. View

3.
Zhao X, Howell K, He S, Brannan J, Wec A, Davidson E . Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017; 169(5):891-904.e15. PMC: 5803079. DOI: 10.1016/j.cell.2017.04.038. View

4.
Pallesen J, Murin C, de Val N, Cottrell C, Hastie K, Turner H . Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol. 2016; 1(9):16128. PMC: 5003320. DOI: 10.1038/nmicrobiol.2016.128. View

5.
Johansen L, Brannan J, Delos S, Shoemaker C, Stossel A, Lear C . FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013; 5(190):190ra79. PMC: 3955358. DOI: 10.1126/scitranslmed.3005471. View